Alternative and complementary therapies in osteoarthritis and cartilage repair

Nicola Veronese, Jean-François Kaux, Emmanuel Maheu, Matijevic, Reginster, Johanne Martel-Pelletier, Nasser Al-Daghri, Cooper, Nicola Veronese, Francis Berenbaum, Philip G Conaghan, Kurth, Germain Honvo, Nicholas Fuggle, Jean-Pierre Pelletier, Roland Roth, Lems, Mila Vlaskovska, Olivier Bruyère, OreffoCortet, Maria Luisa Brandi, Kanis, Rizzoli, Maurizio Cutolo, Price, Thierry Thomas, Jaime Branco

Risultato della ricerca: Articlepeer review

9 Citazioni (Scopus)

Abstract

Osteoarthritis (OA) is the most common joint condition and, with a burgeoning ageing population, is due to increase in prevalence. Beyond conventional medical and surgical interventions, there are an increasing number of ‘alternative’ therapies. These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference (or completely excluded) from current OA guidelines. Thus, the aim of this review was to synthesize the current evidence regarding autologous chondrocyte implantation (ACI), mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP), vitamin D and other alternative therapies. The majority of studies were in knee OA or chondral defects. Matrix-assisted ACI has demonstrated exceedingly limited, symptomatic improvements in the treatment of cartilage defects of the knee and is not supported for the treatment of knee OA. There is some evidence to suggest symptomatic improvement with MSC injection in knee OA, with the suggestion of minimal structural improvement demonstrated on MRI and there are positive signals that PRP may also lead to symptomatic improvement, though variation in preparation makes inter-study comparison difficult. There is variability in findings with vitamin D supplementation in OA, and the only recommendation which can be made, at this time, is for replacement when vitamin D is deplete. Other alternative therapies reviewed have some evidence (though from small, poor-quality studies) to support improvement in symptoms and again there is often a wide variation in dosage and regimens. For all these therapeutic modalities, although controlled studies have been undertaken to evaluate effectiveness in OA, these have often been of small size, limited statistical power, uncertain blindness and using various methodologies. These deficiencies must leave the question as to whether they have been validated as effective therapies in OA (or chondral defects). The conclusions of this review are that all alternative interventions definitely require clinical trials with robust methodology, to assess their efficacy and safety in the treatment of OA beyond contextual and placebo effects. © 2020, The Author(s).
Lingua originaleEnglish
pagine (da-a)547-560
Numero di pagine14
RivistaAging clinical and experimental research
Volume32
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Ageing
  • Geriatrics and Gerontology

Cita questo